Overview

Apremilast Pregnancy Exposure Registry

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the Apremilast Pregnancy Exposure Registry is to monitor planned and unplanned pregnancies exposed to apremilast and to evaluate the safety of this medication relative to specified pregnancy outcomes, and to evaluate potential effects of prenatal apremilast exposure on infant health status through one year of age.
Details
Lead Sponsor:
University of California, San Diego
Collaborators:
Celgene
The Organization of Teratology Information Specialists
Treatments:
Apremilast
Thalidomide